Clinical trial NCT04747587: Non-use After Stroke: Influence of Applied Force and Precision When Reaching With the Paretic Upper Limb
Official title: Non-use après Accident Vasculaire cérébral : Influence de la Force et de la précision du Geste à Fournir Lors Des Mouvements du Membre supérieur parétique
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke
Keywords: Non-use
Compensation
Weakness
Optimal control
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2021-02-10
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The target population corresponds to hemiparetic patients after stroke. The control population corresponds to subjects without neurological disorder. The two groups will be matched on age (18-44, 45-64, 65-79, +80) and sex.

Brief summary: After a stroke, 80% of patients have an upper limb deficit, limiting activity. Some develop a non-use: they can, but do not, use their paretic limb. Non-use is a general phenomenon applied to all situations where the patient applies unnecessary compensation. Several rehabilitation techniques are effective to counter non-use, but there is insufficient knowledge to choose the most suitable technique. Optimal control theory could help guide these choices. It assumes that the chosen coordination satisfies the constraints of the task (force, amplitude, tolerance) while reducing the cost of the movement. This study will assess non-use by anticipating the sensitivity to the constraints of force and precision deduced from the logic of optimal control. The study authors expect to observe a weakness effect: in a reaching task (i.e. when the person has to touch an object placed in front of them), lightening the paretic arm makes it possible to reduce non-use, and a precision effect: in a reaching task, non-use increases with the required spatial precision.


Eligibility criteria: Inclusion Criteria:

Inclusion criteria specific to the stroke group:

* Patient having had a 1st stroke
* Patient whose stroke occurred more than a month ago.
* Patient having had a supratentorial stroke
* Patient able to touch the opposite knee with the paretic arm

Inclusion criteria specific to the control group:

* Subject who has never had a stroke
* Subject without motor or orthopedic impairment of the upper limbs and in particular of the shoulder

General inclusion criteria:

* Subject who has given free and informed consent.
* Subject who signed the consent form.
* Subject affiliated or beneficiary of a health insurance plan.

Exclusion criteria:

* Pregnant, parturient or breastfeeding subject.
* The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Patient with cognitive disorders incompatible with a good understanding of the use of the device
* Patient with other neurological or osteoarticular history that may limit the performance of the task - criterion left to the deiscretion of the investigator

Primary outcomes:
measure: Evaluate the modifications of the proximal non-use after stroke on the paretic side according to the extent of force constraint
timeFrame: Inclusion
Secondary outcomes:
measure: Evaluate the modifications of the proximal non-use after stroke on the paretic side according to the precision required
timeFrame: Inclusion
measure: Evaluate the modifications of the proximal non-use in the control subjects according to the constraints of force or precision
timeFrame: Inclusion
measure: Evaluate the level of neuromuscular activation during reaching
timeFrame: Inclusion
measure: Model the constraints and costs explaining non-use patient by patient, to distinguish between physiological and psycho-behavioral non-use
timeFrame: Inclusion
measure: Time since stroke (acute, subacute or chronic phase)
timeFrame: Inclusion
measure: Intensity of arm deficit
timeFrame: Inclusion
measure: height of the target
timeFrame: Inclusion
Other outcomes:
Locations:
city: Montpellier
country: France
facility: CHU de Montpellier
city: Nîmes
country: France
facility: CHU de Nîmes
Study officials:
affiliation: Centre Hospitalier Universitaire de Nīmes
name: Jérôme Froger
role: PRINCIPAL_INVESTIGATOR
References: